Evidence map›Paper›PMID 29168484›Full record

ArticleNature chemistry2017

Global profiling of lysine reactivity and ligandability in the human proteome.

Stephan M Hacker, Keriann M Backus, Michael R Lazear, Stefano Forli, Bruno E Correia, Benjamin F Cravatt

Open access · bronzeAbstract read
In one paragraph

Article in Nature chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 478 citations in OpenAlex.

  1. Article
  2. Precision Chemistry for Protein Lysine Modification.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Article
  4. 2-Alkyl Furans Undergo Radiolytic Oxidative Protein Cross-Linking.Journal of the American Chemical Society · 2026
    Article
  5. Article
  6. SuFEx-Enabled Reprogramming of Flavonoids for Selective α-Glucosidase Covalent Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. RSC chemical biology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026
    Review
  18. Article
  19. Mapping the SHP2 Allosteric Pocket With Target-Biased Covalent Fragments.Chembiochem : a European journal of chemical biology · 2026
    Article
  20. Regulation of RNA-binding proteins by small biomolecules.Nature reviews. Molecular cell biology · 2026
    Review

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Stephan M HackerDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92307, USA.ORCID 0000-0001-5420-4824
Keriann M BackusDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92307, USA.ORCID 0000-0001-8541-1404
Michael R LazearDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92307, USA.
Stefano ForliDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92307, USA.ORCID 0000-0002-5964-7111
Bruno E CorreiaLaboratory of Protein Design & Immunoengineering, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
Benjamin F CravattDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92307, USA.ORCID 0000-0001-5330-3492
Scripps Research Institute · USÉcole Polytechnique Fédérale de Lausanne · CH

Funding

AutoDock Suite: Next Generation Environment for Drug DesignR01GM069832 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI FORLI, STEFANO · 2004 to 2025
$10.9M
Chemical Probes for Metabolic Pathway Discovery in Human DiseaseR01CA132630 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2007 to 2018
$5.1M
Chemical Approaches for Activity-Based ProteomicsR37CA087660 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2009 to 2018
$3.1M
CHEMICAL APPROACHES FOR ACTIVITY BASED PROTEOMICSR01CA087660 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2000 to 2008
$2.8M
Fragment-Based Ligand Discovery in ProteomesF32GM108208 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI BACKUS, KERIANN MARIE · 2013 to 2014
$102k
NCI NIH HHS R01 CA087660NCI NIH HHS R01 CA132630NCI NIH HHS R37 CA087660NIGMS NIH HHS F32 GM108208NIGMS NIH HHS R01 GM069832
6 · The paper itself

Abstract

Nucleophilic amino acids make important contributions to protein function, including performing key roles in catalysis and serving as sites for post-translational modification. Electrophilic groups that target amino-acid nucleophiles have been used to create covalent ligands and drugs, but have, so far, been mainly limited to cysteine and serine. Here, we report a chemical proteomic platform for the global and quantitative analysis of lysine residues in native biological systems. We have quantified, in total, more than 9,000 lysines in human cell proteomes and have identified several hundred residues with heightened reactivity that are enriched at protein functional sites and can frequently be targeted by electrophilic small molecules. We have also discovered lysine-reactive fragment electrophiles that inhibit enzymes by active site and allosteric mechanisms, as well as disrupt protein-protein interactions in transcriptional regulatory complexes, emphasizing the broad potential and diverse functional consequences of liganding lysine residues throughout the human proteome.

Indexed as

HumansLigandsLysineProteomeProteomicsLigandsLysineProteome

Identifiers

PMID29168484
PMCPMC5726523
OpenAlexW2742118221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.